- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04950842
Induction of Transplant Tolerance in LDLT Via iTS
Phase I/II Study to Evaluate the Safety and Efficacy of JB-101(Induced T Cell With Suppressing Functions), to Induce Operational Tolerance in Living Donor Liver Transplantation.
The purpose of this clinical trial is to examine the immunotolerance-inducing ability (effectiveness) of induced inhibitory T cells JB-101 in patients with living-donor liver transplantation using "whether or not operational tolerance is achieved" as an index.
And the safety of JB-101 will be evaluated.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This trial is a phase I / II, open-label, single-arm, multicenter clinical trial of JB-101, an inducible inhibitory T cell, in patients with end-stage liver failure who undergo living-donor liver transplantation.
The primary endpoint of efficacy is withdrawal from immunosuppressant by 78 weeks (up to 91 weeks) after liver transplantation, and then "whether or not operational tolerance is achieved".
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Saori Hirota
- Phone Number: +81-70-1000-8906
- Email: s.hirota.zk@juntendo.ac.jp
Study Contact Backup
- Name: Tatsunori Toyonaga
- Phone Number: +81-70-4193-4337
- Email: toyonaga@juntenbio.co.jp
Study Locations
-
-
-
Hiroshima, Japan
- Hiroshima University Hospital
-
Kyoto, Japan
- Kyoto University Hospital
-
Nagasaki, Japan
- Nagasaki University Hospital
-
-
Tokyo
-
Bunkyoku, Tokyo, Japan
- Juntendo University Hospital
-
Shinjuku, Tokyo, Japan
- Tokyo Women's Medical University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients with end-stage liver failure undergoing living-donor liver transplantation.
Subjects who are healthy physically and psychologically and willing to donate organs voluntarily.
Relative within the second degree of relationship or partner. (Acceptable degree conforms eligibility criteria of the institution.)
Exclusion Criteria:
Patients who have clinical findings of active infection.
Patients with advanced heart disease, fulminant hepatitis in liver failure, renal disease, malignant tumors and complications of immunodeficiency.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: JB-101
induced T cell with suppressive function
|
induced T cell with suppressive function
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Achievement of operational tolerance
Time Frame: immunosuppressive drug cessation was maintained for at least 12 months
|
Achievement of "Operational Tolerance" defined as no biopsy proven rejection diagnosed by Banff criteria for more than 52 weeks after withdrawal of immunosuppressive drugs post transplant
|
immunosuppressive drug cessation was maintained for at least 12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Koichiro Uchida, M.D.,Ph.D., Juntendo University Advanced Research Institute for Health Science
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- jRCT2073200067
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Living-donor Liver Transplantation
-
Seoul National University HospitalRecruitingLiving Donor Liver TransplantationKorea, Republic of
-
Angus W. Thomson PhD DScActive, not recruitingLiving Donor Liver TransplantationUnited States
-
Fudan UniversityCompletedLiving Donor Liver Transplantation
-
University Health Network, TorontoRecruitingLiving Donor Liver TransplantationCanada
-
Asan Medical CenterMinistry of Health & Welfare, KoreaCompletedLiving Donor Liver TransplantationKorea, Republic of
-
Seoul National University HospitalOneclickmedical Co., Ltd. (Seoul, South Korea)Not yet recruitingLiving Donor Liver TransplantationKorea, Republic of
-
Angus W. Thomson PhD DScUniversity of PittsburghActive, not recruiting
-
Mansoura UniversityUnknownLiving Donor Liver Transplantation RecipientsEgypt
-
University of AlbertaUniversity Hospital FoundationActive, not recruitingLiving Donor Kidney TransplantationCanada
-
University of AlbertaAlberta Innovates Health SolutionsRecruitingLiving Donor Kidney TransplantationCanada
Clinical Trials on JB-101
-
Minia UniversityCompleted
-
Johnson & Johnson Consumer and Personal Products...Fudan University; Beijing Children's Hospital; Shanghai China-Norm Management... and other collaboratorsCompletedBaby Skin DevelopmentChina
-
GlaxoSmithKlineCompleted
-
University College CorkCompleted
-
TR TherapeuticsCompleted
-
Abalonex, LLCNot yet recruitingTraumatic Brain Injury | Cerebral Edema
-
Benjamin IzarTerminatedLeiomyosarcoma | LiposarcomaUnited States
-
Flame BiosciencesCompletedHealthy SubjectsUnited States
-
Alaunos TherapeuticsCompleted
-
Alaunos TherapeuticsCompletedLymphoma | Multiple Myeloma | Acute Leukemia | Chronic Myeloproliferative Disease | Chronic Lymphoproliferative Disease | Poor-risk Myelodysplasia (MDS)United States